Latham & Watkins Advises scPharmaceuticals in Acquisition by MannKind Corporation

scPharmaceuticals Inc. (Nasdaq: SCPH) and MannKind Corporation (Nasdaq: MNKD) have announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals. The acquisition is expected to diversify and accelerate revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing a significant unmet need. The acquisition strengthens MannKind’s organization by integrating scPharmaceuticals’ established commercial and medical capabilities into MannKind’s existing infrastructure. This proposed acquisition marks MannKind’s strategic expansion into cardiorenal medicine, establishing the company’s cardiometabolic business alongside its orphan lung division.

Latham & Watkins LLP advised scPharmaceuticals in the transaction with a corporate team led by partners Wesley Holmes, Scott Shean, Bret Stancil, Elisabeth Martin, and Peter Handrinos, counsel Alexandra McArthur, and associates Elena Burns, Rebekah Bingham, Kirstin Chubb, and Jennifer Pitsch. Advice was also provided on benefits matters by partner Josh Friedman, with associates Rebecca Fishbein and Imara Joroff; on tax matters by partner Katharine Moir, with associate Dennis Poehland; on healthcare/FDA regulatory matters by partner Betty Pang and counsel Chad Jennings; on finance matters by partner Elizabeth Oh, with associate Rychelle Andersen; on data privacy matters by partner Heather Deixler, with associate Zac Alpert; on antitrust matters by partner Patrick English, with associate Nathaniel Amann; on securities litigation matters by partner Kristin Murphy, with associate Sonya Shaikh; and on intellectual property matters by partner Steven Chinowsky, with associate Dylan O’Connor.